Search the Newsreel

Piper Sandler Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)

Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Crispr Therapeutics AG (CRSP) with a price target of $110.00. This follows similar Buy ratings from William Blair, though Morgan Stanley maintained a Hold. The company recently reported Q2 revenue of $10.18 million and …

Acrivon Therapeutics (ACRV) Projected to Post Earnings on Wednesday

Acrivon Reports 3 Lung Cancer Subjects on Treatment for Over a Year

Acrivon Therapeutics announced that its drug candidate, ACR-2316, a WEE1/PKMYT1 inhibitor, has advanced to randomized dose expansion in its Phase 1/2 study. This progression is based on a favorable safety profile and observed clinical activity, including tumor shrinkage and partial responses, with three lung …

Strata Critical Medical, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:SRTA)

This article provides the slide deck published by Strata Critical Medical, Inc. (SRTA) in conjunction with their Q2 2026 earnings call. The content is presented by SA Transcripts, a team dedicated to publishing earnings call transcripts and related developments.

Strata Critical Medical, Inc. 2Q 2026: Revenue $72.51M, EPS ($0.12) — 10-Q Summary

Strata Critical Medical, Inc. reported its Q2 2026 financial results, showing revenue of $72.51 million, a 60.7% increase year-over-year, largely due to Logistics expansion and newly acquired Clinical services. The net loss widened to ($10.52M) with a diluted loss per share of ($0.12). The …

Criteo S.A. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:CRTO) 2026-08-05

Criteo S.A. published its Q2 2026 earnings call presentation, detailing financial results. The company reported an EPS of $0.80, beating estimates by $0.11, but revenue of $255.47M missed expectations by $7.95M, representing a 12.53% year-over-year decrease. The slide deck accompanies their recent earnings call.

Criteo (CRTO) Earnings Date and Reports 2026 $CRTO

Criteo (Nasdaq: CRTO) Q2 2026 earnings fall as media segments soften

Cricut earnings beat by $0.14, revenue fell short of estimates

Criteo sinks as weak outlook overshadows earnings beat (CRTO:NASDAQ)

Top Metal and Mining Stocks to Watch: Why Is Critical Resources (ASX:CRR) Under the Spotlight?

Cricut, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:CRCT) 2026-08-05

Cricut, Inc. Q2 2026 Earnings Call Summary - Moby Strategic Execution and Platform Dynamics Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. …

Cricut (CRCT) Stock Jumps As One Off Gains Cloud Profit Surge

Cricut (CRCT) saw its stock jump 23% after reporting Q2 net income of US$39.1m on US$156.3m revenue, largely due to tariff refunds and a royalty settlement. While the profit surge makes the company's valuation look appealing, questions remain about the sustainability of these gains, …

Crispr Earnings: Casgevy Gains Traction as Commercial Hurdles Begin to Ease

Crizac makes Q1FY27 earnings call audio available for investor review

Critical Resources (ASX:CRR) Rises as Mavis Lake Adds Land and New Targets

Strata Critical Medical Inc (SRTA) (Q2 2026) Earnings Call Highlights: Revenue Surges 60. ...

Strata Critical Medical Inc (SRTA) reported a 60.7% year-over-year revenue increase to $72.5 million in Q2 2026, driven by strong clinical revenue growth and strategic acquisitions. The company raised its full-year 2026 revenue and adjusted EBITDA guidance, citing outperformance in its base business and …

Earnings call transcript: Cricut tops EPS forecast in Q2 2026 as revenue slips

CRISPR Therapeutics AG Stock 12‑Month Price Target Raised to $84.39, Implies 70% Upside

The average 12-month price target for CRISPR Therapeutics AG (CRSP) stock has been raised to $84.39 from $83.94, based on estimates from 18 analysts. This updated target implies a potential upside of approximately 70% from its Aug. 3 closing price. The consensus rating among …

Crinetics Pharmaceuticals stock hits all-time high at 84.01 USD

Crinetics Pharmaceuticals' stock has reached an all-time high of $84.01, driven by a 187.21% increase over the past year and a market capitalization of $8.85 billion. This surge in value comes as Vertex Pharmaceuticals announced an agreement to acquire Crinetics for approximately $10 billion, …

Cricut (CRCT) insider files Form 144 to sell 60,000 Class A shares

Cricut insider Ashish Arora has filed a Form 144, indicating an intent to sell 60,000 Class A common shares of Cricut, Inc., valued at approximately $296,400, through Goldman Sachs & Co. LLC. The proposed sale is expected around August 4, 2026, on NASD. The …

Crinetics Pharmaceuticals (CRNX) On Vertex Deal Optimism And Results Looks Nearly Fully Valued

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Crinetics Pharmaceuticals (CRNX) is in focus after reporting second quarter 2026 results that paired …

Strata Critical Medical Q2 Results: Revenue Jumps 60.7% YoY

Cricut, Inc. Reports Second Quarter 2026 Financial Results

Cricut, Inc. announced its second-quarter 2026 financial results, reporting $156.3 million in revenue, a 9% decrease from Q2 2025, but a 59% increase in net income to $39.1 million. The company grew its paid subscribers to over 3.1 million, up 3% year-over-year, and saw …

Vertex Pharmaceuticals' Solid Q2, Raised Outlook Underscore Core Business Strength, RBC Says

Vertex Pharmaceuticals (VRTX) reported a solid Q2 and raised its outlook, highlighting the strength PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a …

Crinetics Pharmaceuticals (NASDAQ:CRNX) Hits New 52-Week High After Better-Than-Expected Earnings

Crispr Therapeutics Posts "Quiet" Quarter as Casgevy Advances, SiRNA Data Readouts Near, RBC Says

Crispr Therapeutics (CRSP) reported a relatively quiet Q2, with Casgevy continuing to gain commercia PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a …

Strata Critical Medical (NASDAQ: SRTA) grows revenue but posts Q2 loss

CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates

CRISPR Therapeutics (CRSP) reported a narrower-than-expected loss of 94 cents per share for Q2 2026, surpassing the Zacks Consensus Estimate of a $1.10 loss. The company's total revenues also exceeded expectations, reaching $10.2 million against an estimate of $7 million, driven by strong collaboration …

VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised

Vertex Pharmaceuticals VRTX reported adjusted earnings of $4.73 per share for the second quarter of 2026, missing the Zacks Consensus Estimate of $4.79. Earnings, however, rose around 4.6% year over year on higher product revenues. Second-quarter total revenues of $3.33 billion beat the Zacks …

Cricut (CRCT) holder files to sell 60,000 Class A shares under Rule 144

A shareholder of Cricut, Inc. (CRCT), Ashish Arora, has filed a notice under Rule 144 to sell up to 60,000 Class A Common Stock shares. The sale, valued at approximately $364,200, is expected to occur on August 5, 2026, through Goldman Sachs & Co. …

Strata Critical Medical Releases Q2 2026 Financial Results

Strata Critical Medical (NASDAQ: SRTA) reported its Q2 2026 financial results, with diluted EPS of -$0.12, missing the $0.01 estimate. Despite a 60.7% increase in revenue to $72.5M year-over-year, the company experienced a net loss of $10.5M, widening its per-share loss from Q2 2025. …

Vertex Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary

Vertex Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary - Moby Strategic Execution and Portfolio Expansion Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap …

Vertex (VRTX) Buys Crinetics To Push Beyond Cystic Fibrosis

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Vertex Pharmaceuticals (NasdaqGS:VRTX) has agreed to acquire Crinetics Pharmaceuticals in a deal expected to …

Strata Critical Medical Reports Q2 2026 Revenue Up 60.7% to $72.5M; Adjusted EBITDA $7.9M

Strata Critical Medical (SRTA) reported a significant revenue increase of 60.7% year-over-year, reaching $72.5 million in Q2 2026, primarily driven by the expansion of its Clinical business. The company posted an Adjusted EBITDA of $7.9 million (10.9% margin) and a GAAP net loss of …

Blade Air Mobility reports mixed Q2 results; updates FY26 outlook

* Blade Air Mobility press release [https://seekingalpha.com/pr/20605368-strata-critical-medical-announces-second-quarter-2026-results] (SRTA [https://seekingalpha.com/symbol/SRTA]): Q2 GAAP EPS of -$0.12 misses by $0.10. * Revenue of $72.51M (+60.7% Y/Y) beats by $4.9M. * _Adjusted EBITDA__(1)__ of $7.9 million in Q2 2026; Adjusted EBITDA margin of 10.9%_ * _Cash flow from …